Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

ABSTRACT: The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.

DISEASE(S): Gastro-intestinal Stromal Tumour,Gastrointestinal Stromal Tumor,Stromal Gastrointestinal Cancer,Tumor Del Estroma Gastrointestinal,Gastrointestinal Stromal Tumors

PROVIDER: 2156727 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR